Helmerich & Payne Inc. Common Stock vs BIO-TECHNE Corp — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.25 (market cap $3.86B), while BIO-TECHNE Corp trades at $72.69 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 2.9× Helmerich & Payne Inc. Common Stock's market cap, and Helmerich & Payne Inc. Common Stock pays the higher dividend (2.59%). Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and BIO-TECHNE Corp for 64 Days on average.
| HP | TECH | |
|---|---|---|
Market Cap | $3.86B | $11.37B |
Volume | 870,371 | 1,544,768 |
Sector | Energy | Health |
52-Week High | $47.64 | $72.61 |
52-Week Low | $23.11 | $43.31 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $5.49B | $11.40B |
Dividend Yield | 2.59% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bio-Techne (TECH) trades at $72.48, down 0.11% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average support. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. The company's pending acquisition by Merck KGaA for $73.00 per share, approved by shareholders (PRNewsWire, 2026-09-23), is a key near-term catalyst. Fundamentals indicate solid profitability with a 65.77% gross margin but elevated valuation ratios like a P/E of 62.52.
The outlook is dominated by the acquisition, offering a clear exit near the current price. Upside is capped by the deal price, while execution risks or regulatory hurdles pose downside. Analyst sentiment is neutral with a consensus hold rating. The stock presents a low-risk opportunity for merger arbitrage but limited growth potential for long-term investors absent competitive threats or integration challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.
Read more on HP →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →